Jerri Rook
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read MoreFeb 22, 2022
-
Vanderbilt extends its longest ongoing drug discovery agreement with pharmaceutical company through 2023
Vanderbilt has extended its longest ongoing drug discovery agreement with Osaka, Japan-based Ono Pharmaceutical Co., Ltd., a research and development-oriented pharmaceutical company that is committed to creating innovative medicines in specific areas, through November 2023. Read MoreDec 21, 2021
-
Jerri Rook is awarded the Alzheimer’s Drug Discovery Foundation’s prestigious Melvin R. Goodes prize
Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research. Read MoreNov 2, 2020
-
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read MoreJun 16, 2020
-
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read MoreAug 7, 2017